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Objectives This study sought to determine the characteristics and long-term prognosis of anemia in ambulatory patients
with chronic heart failure.
Background Anemia is prevalent in heart failure, and may portend poor outcomes.
Methods We reviewed 6,159 consecutive outpatients with chronic stable heart failure at baseline, short-term (3-month)
follow-up, and long-term (6-month) follow-up between 2001 and 2006. Clinical, demographic, laboratory, and
echocardiographic data were reviewed from electronic medical records. Mortality rates were determined from
6-month follow-up to end of study period.
Results Prevalence of anemia (hemoglobin [Hb] 12 g/dl for men, 11 g/dl for women) was 17.2% in our cohort. Diabetes,
B-natriuretic peptide, left ventricular ejection fraction, and estimated glomerular filtration rate were independent pre-
dictors of baseline anemia. Documented evaluation of anemia was found in only 3% of all anemic patients, and bet-
ter in internal medicine than in cardiology clinics. At 6-month follow-up, new-onset anemia developed in 16% of pa-
tients without prior anemia, whereas 43% patients with anemia at baseline had resolution of their hemoglobin levels.
Higher total mortality rates were evident in patients with persistent anemia (58% vs. 31%, p  0.0001) or with inci-
dent anemia (45% vs. 31%, p  0.0001) compared with those with without anemia at 6 months.
Conclusions These observations in a broad unselected outpatient cohort suggest that anemia in patients with heart failure is
under-recognized and underevaluated. However, resolution of anemia was evident in up to 43% of patients who pre-
sented initially with anemia, and did not pose greater long-term risk for all-cause mortality. However, the presence of
persistent anemia conferred poorest survival in patients with heart failure when compared with that of incident, re-
solved, or no anemia. (J Am Coll Cardiol 2008;51:569–76) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.094a
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wnemia has become increasingly recognized as an important
actor in the development and progression of heart failure.
nemia occurs with surprisingly high prevalence and por-
ends a poor prognosis (1–3). In a cohort of 1,061 patients
ith advanced heart failure referred for transplant evalua-
ion, lower hemoglobin (Hb) was associated with greater
unctional impairment, worse exercise capacity, and in-
reased mortality (4). However, most analyses have been
imited to data sets from hospitalized patients (5), post-hoc
nalyses of clinical trials with primarily baseline measure-
ents (6), or interrogation of large administrative databases
7). Bias of ascertainment in these populations can limit the
rom the *Department of Cardiovascular Medicine, †Department of Internal
edicine, and ‡Information Technology Division, Cleveland Clinic, Cleveland,
hio. Drs. Tang, Francis, and Young are consultants for Amgen, Inc.u
Manuscript received May 14, 2007; revised manuscript received July 20, 2007,
ccepted July 23, 2007.pplicability of their observations (8). Furthermore, data
egarding the changes in Hb levels in patients over time and
he impact on prognoses remain limited.
See page 577
Because of the implementation of an electronic medical
ecord system in our practice since 2001, we have the ability
o characterize anemia in an unselected cohort of ambula-
ory patients with a clinical diagnosis of chronic heart failure
een in internal medicine and cardiology clinics. The objec-
ive of this paper is to determine the prevalence and
haracteristics of anemia in ambulatory patients with
hronic heart failure and to identify the impact of changes in
nemia status over time to long-term survival across patients
ith varying degrees of renal insufficiency and left ventric-
lar systolic function.
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Study population. The Cleve-
land Clinic Institutional Review
Board approved this study proto-
col. We reviewed our heart fail-
ure registry compiled from an
electronic medical record system
(EpicCare, Epic Systems Corp.,
Madison, Wisconsin), identified
6,159 consecutive ambulatory
patients seen at the Cleveland
Clinic internal medicine or car-
diology outpatient clinics with a
documented clinical diagnosis of
heart failure, and performed a
complete blood count test be-
tween January 2001 and April
006. The EpicCare system provides a choice of common
iagnoses with corresponding International Classification of
iseases-Ninth Revision (ICD-9) codes to document clin-
cal problems in clinical chart notes. We therefore con-
rmed the diagnosis by performing a search for the ICD-9
odes related to heart failure to establish our study cohort:
42.9, 398.91, 402.01, 402.11, 402.91, 404.01, 404.03-4,
04.13, 404.91, 404.93, 425.1, 425.4-5, 425.7-9, 428.0-1,
nd 428.9. Patients must also have had documented left
entricular ejection fraction (LVEF) data within 100 days of
he baseline Hb blood analysis for inclusion in the study.
We excluded patients with a history of congenital heart
isease, malignancies or inherited or acquired anemia
ICD-9 code 282.x to 285.x), or documented active gastro-
ntestinal bleeding at the time of blood draw. If a patient
as seen at both internal medicine and cardiology clinics, he
r she would be classified as being followed up in the
ardiology clinic.
ata synthesis. Clinical, demographic, laboratory, and
ocumented primary and secondary diagnoses in the elec-
ronic medical record were reviewed. All clinical data were
atched to within 100 days of baseline Hb blood analysis,
ith the first occurrence defined as baseline. Body mass
ndex and body surface area were derived from height and
eight measurements. Estimated glomerular filtration rate
eGFR) was calculated through the Modification of Diet in
enal Disease equation (9). Long-term all-cause mortality
ata were determined from electronic medical records and
alidated by the social security death index. Death and
ardiac transplantation dates were used in survival analysis
censoring transplantation), and all patients were followed
p until June 20, 2007.
We defined anemia using a conservative criteria: Hb12
/dl for men and 11 g/dl for women. Standard criteria for
icrocytic (mean corpuscular volume [MCV] 82 fl) and
acrocytic (MCV98 fl) anemia were used. For those with
nemia identified by blood work, diagnostic ICD-9 coding
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BNP  B-type natriuretic
peptide
eGFR  estimated
glomerular filtration rate
Hb  hemoglobin
ICD-9  International
Classification of Diseases-
Ninth Revision
LVEF  left ventricular
ejection fraction
MCV  mean corpuscular
volumeor anemia (280.x to 281.x), and standard evaluation tests dincluding iron studies, reticulocyte count, vitamin B12 and
olate levels, and gastrointestinal bleeding workup) were
dentified.
Short-term follow-up was defined as the next available
b measurement within 3 months from baseline, which
esults in a mean 0.6  0.8 months of follow-up. Patients
ust also have had consecutive Hb measurements within
00 days of the 6-month follow-up to be included in the
ong-term follow-up (mean follow-up at 5.3 1.8 months).
ncidence of (new-onset) anemia was defined as the pres-
nce of anemia at short-term (3-month) or long-term
6-month) follow-up in those patients without anemia at
aseline. Resolution of anemia was classified as normaliza-
ion of Hb levels (12 g/dl for men and 11 g/dl for
omen) with at least improvement in 0.5 g/dl at
ollow-up in those who presented with anemia at baseline.
ersistent anemia was said to be present if patients had
nemia at both baseline and at short-term or long-term
ollow-up. Proportions of incidence, resolution, and persis-
ence of anemia were determined relative to the total
umber of patients at follow-up. Changes in Hb levels over
he course of follow-up within the study period were also
etermined.
All echocardiograms and laboratory testing were per-
ormed at the Cleveland Clinic and reported in EpicCare.
chocardiographic left atrial diameter and area, interven-
ricular septal thickness, posterior wall thickness, left ven-
ricular end-diastolic diameter, and LVEF were collected.
he LVEF was determined by the Simpson rule, whereas
eft atrial area was determined from the area–length method
s a gross surrogate of diastolic function (10). The LV mass
as calculated using the American Society of Echocardiog-
aphy equation, defined as 0.8 ([(interventricular septal
hickness  posterior wall thickness  left ventricular
nd-diastolic diameter)3  left ventricular end-diastolic
iameter3]  0.6) adjusted for gender (10). Standard LV
iastolic filling pattern was graded on a scale from I to IV
ased on mitral inflow E- and A-wave velocity profiles
escribed previously (11,12). Mitral regurgitation and tri-
uspid regurgitation severity was evaluated on a scale from 0
o 4, with 0 representing normal and 4 signifying severe
egurgitation by color Doppler inflow patterns. Right ven-
ricular systolic pressure was determined from estimated
ugular venous pressure and maximum tricuspid regurgita-
ion velocity using the modified Bernoulli equation.
tatistical analyses. Results are presented in percentages
for dichotomous variables) or mean  standard deviation
for continuous variables). Univariable analyses were per-
ormed using 2-tailed chi-square and Student t tests, re-
pectively. Multivariable logistic regression with forward
tepwise selection was performed to determine the predic-
ors of baseline prevalence of anemia in our cohort (variables
ncluded baseline age, gender, hypertension, diabetes,
CV, medications (angiotensin-converting enzyme [ACE]
nhibitors/angiotensin receptor blockers, beta-blockers, loop
iuretics), B-type natriuretic peptide (BNP), eGFR, LVEF,
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February 5, 2008:569–76 Anemia in Ambulatory Heart Failure Patientsnd left atrial area). Trends for the prevalence of anemia
cross different predictors were assessed with the Cochran-
rmitage test. Linear univariate correlation assessed rela-
ions between changes in Hb and changes in clinical status.
ultivariate correlation to changes in Hb used a stepwise
odel followed by standard least-squares fit. Survival was
nalyzed between patients with incident, resolved, or per-
istent anemia versus those without anemia using Kaplan-
eier analysis. Long-term mortality data over a mean
ollow-up of 3.9  2.2 years were used to calculate time to
eath or end of follow-up (censoring cardiac transplanta-
ion) in survival analysis. Multivariate Cox proportional
azards model was used to calculate risk ratios for indepen-
ent predictors of mortality with incremental increases in
ontinuous variables. A p value of 0.05 was considered
tatistically significant. All statistical analyses were per-
ormed using SAS version 9.1 and JMP version 5.1 (SAS
nstitute, Cary, North Carolina).
esults
total of 6,159 outpatients with a clinical diagnosis of heart
ailure met the study inclusion and exclusion criteria (in-
luding 3,360 and 2,796 patients initially presenting in
nternal medicine and cardiology clinics, respectively). The
ean baseline Hb level was 14  2 g/dl in men and 13 
g/dl in women in the overall study cohort. The majority of
ur patients in the cohort had been treated with ACE
nhibitors, beta-blockers, and loop diuretics at baseline
Table 1). The median LVEF was 30%, and median plasma
NP level was 325 pg/ml for those with available data at
aseline (n 2,128). Among the overall study cohort, 1,393
atients (23%) had complete blood count data available at
oth short-term (3-month) and long-term (6-month)
ollow-up time points (Fig. 1).
revalence of anemia. At baseline, the prevalence of ane-
ia was 17.2% (17.8% in men, 16.0% in women, n 6,159)
Fig. 1). At follow-up, the prevalence of anemia at baseline
n the subgroup was 23.2% (n  1,393), similarly when
ssessed at 3- and 6-month follow-up. Baseline character-
stics between patients with versus without anemia are
hown in Table 1. Patients with anemia were older, had
ore prevalent diabetes mellitus and heart failure medica-
ion usage; had higher mortality rates, BNP, and blood urea
itrogen; and had lower eGFR, low-density lipoprotein,
nd more severe diastolic dysfunction (both diastolic stage
nd left atrial area as surrogate measure). A higher preva-
ence of anemia was associated with male gender, particu-
arly at age 75 years (Fig. 2). Patients with moderately
mpaired renal function (eGFR 60 ml/min/1.73 m2),
ore preserved LVEF above median (30%), and above
edian plasma levels of BNP (325 pg/ml) had signifi-
antly higher prevalence of anemia (Fig. 3). These factors
ere found to be independent predictors of the prevalence
f anemia in heart failure patients after multivariate logistic
egression analyses (Table 2). 9atterns of diagnostic evaluation and treatment of ane-
ia. The majority (71.6%) were normocytic (MCV 82 to
aseline Characteristics
Table 1 Baseline Characteristics
Baseline Variable
No Anemia
(n  5,101)
Anemia
(n  1,058) p Value
Clinical data
Age (yrs) 65 14 69 14 0.0001
Gender (% male) 67 64 0.046
Race (% Caucasian) 82 79 0.007
Heart rate (beats/min) 74 13 75 13 0.10
Body mass index (kg/m2) 30 7 29 7 0.23
Systolic blood pressure
(mm Hg)
120 23 117 24 0.037
Diabetes mellitus (%) 25 35 0.0001
Hypertension (%) 43 39 0.019
Myocardial infarction (%) 43 44 0.36
Mortality rate (%) 26 47 0.0001
Laboratory data
Hemoglobin (g/dl) 13.9 1.4 10.4 1.1 0.0001
Mean corpuscular
volume (fl)
90 6 88 8 0.0001
B-type natriuretic peptide
(pg/ml)
529 702 962 1,007 0.0001
Blood urea nitrogen (mg/dl) 24 14 38 24 0.0001
Total cholesterol (mg/dl) 183 51 154 45 0.0001
Low-density lipoprotein
cholesterol (mg/dl)
105 40 84 33 0.0001
Triglycerides (mg/dl) 171 166 148 141 0.0005
Sodium (mEq/l) 140 13 139 14 0.0001
Serum creatinine (mg/dl) 1.20 0.74 1.79 1.36 0.0001
Estimated GFR
(ml/min/1.73 m2)
72 27 57 36 0.0001
Medications
Iron supplementation (%) 7 21 0.0001
Erythropoiesis stimulating
agents (%)
1 8 0.0001
ACE inhibitor/ARB (%) 72/21 65/21 0.0001
Beta-blocker (%) 77 69 0.0001
Calcium channel blocker (%) 22 24 0.032
Digitalis (%) 39 30 0.0001
Nitrates (%) 37 44 0.0001
Statin (%) 55 52 0.072
Loop diuretic (%) 80 86 0.0001
Thiazide diuretic (%) 18 24 0.0001
Echocardiographic data
LV ejection fraction (%-U) 34 17 35 17 0.025
LV end-diastolic
diameter (cm)
6.4 1.0 6.4 1.2 0.080
LA area (cm2) 27 9 29 9 0.0001
Estimated LV mass (g) 281 105 281 102 0.93
LV wall motion score 1.8 0.6 1.8 0.6 0.69
Diastolic stage II (%) 46 60 0.0001
MR severity 3 (%) 17 20 0.010
RV systolic pressure
(mm Hg)
39 14 43 14 0.0001
TR severity 3 (%) 10 20 0.0001
CE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; GFR  glomerular
ltration rate; LA  left atrial; LV  left ventricular; MR  mitral regurgitation; RV  right
entricular; TR  tricuspid regurgitation.8 fl). Microcytic (MCV 82 fl) and macrocytic (MCV
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atients, respectively, with more microcytic anemia in
omen (24.9% vs. 17.0%, p  0.0001), whereas macrocytic
nemia had similar prevalence between genders (6.9% vs.
.7%, p  0.082). Using ICD-9 codes and standard
aboratory workup orders for anemia, only 3.0% of patients
ith heart failure had documented anemia evaluation. Of
nterest, anemia was detected and evaluated more often in
atients presenting to internal medicine clinics than cardi-
logy clinics (18.1% vs. 16.1% from laboratory data, p 
.0001; 3.6% vs. 2.3% from documentation of diagnosis in
roblem list, p 0.0002), although patients seen in internal
edicine clinics were older, were more often women, and
ere more likely to have preserved LV function. As ex-
ected, patients with anemia were more likely to be treated
ith iron supplementation (21% vs. 7%, p  0.0001) or
rythropoiesis-stimulating agents (8% vs. 1%, p  0.0001).
areful chart review showed that those on anemia treatment
n the nonanemia group had a prior diagnosis of anemia or
enal insufficiency in their medical records (data not shown).
owever, nearly 70% of patients who fulfilled the criteria
or anemia did not have a documented follow-up complete
lood count in the electronic medical record within the 6
onths of follow-up after the initial low Hb level.
hanges in anemia status andHb levels over time. Follow-up
atients had consecutive Hb data at 3- and 6-month
ollow-up (n  1,393). In the 6-month follow-up cohort,
10 patients (15.1% of cohort, or 19.6% of patients with no
nemia at baseline) developed new-onset anemia, 143 pa-
ients (10.3% of cohort, or 43.0% of patients with anemia at
aseline) had resolution of their Hb levels, and 180 patients
12.9% of cohort, or 55.7% of patients with anemia at
aseline) had persistent anemia (Fig. 1). Mean changes in
b levels over 6 months were 0.32  1.4 g/dl for those
Figure 1 Prevalence and Resolution
of Anemia in the Study Population
This is a flow diagram describing subject selection according to anemia status
in the total population (n  6,159) as well as in the subgroup with follow-up
hemoglobin levels (n  1,393).ithout anemia, 2.44  1.7 g/dl for those with resolvednemia, 2.59  1.4 g/dl for those with incident anemia,
nd 0.04  1.4 g/dl for those with persistent anemia. All
ohorts, except the persistent anemia cohort (p 0.77), had
ignificant changes in Hb at 6-month follow-up from
aseline (p  0.0001 for the other 3 subgroups). Changes
n clinical and echocardiographic variables identified
rom Table 1 were not correlated with changes in Hb
r  0.10 for all). However, patients with LVEF 30%
median LVEF), BNP 325 pg/ml (median plasma
evels of BNP), eGFR 60 ml/min/1.73 m2, or diabetes
ellitus were more likely to have persistent anemia rather
han no anemia or transient anemia (Fig. 3). Patients
ith eGFR 60 ml/min/1.73 m2 also had a higher rate
f incident anemia.
ong-term prognosis. During a mean follow-up of 3.9 
.2 years, 1,827 patients (30%) died. Incremental changes
n Hb levels were independently attributed to higher
ikelihood of survival after adjusting for LVEF and eGFR
Table 3). At baseline, patients presenting with anemia
ad a significantly worse prognosis than those without
nemia, with an estimated 18.6% increased absolute risk
f death at 3 years (overall mortality 47% vs. 26%, p 
.0001) (Fig. 4). In the subset of patients with follow-up
b levels, patients with persistent anemia still had the
orst survival relative to those with new-incident, resolved,
r no anemia at short-term follow-up (chi-square  81.2)
Fig. 4). At 6 months, patients with persistent anemia or
ncident anemia had higher all-cause mortality risk than
atients without anemia at baseline (all-cause mortality 58%
s. 45% vs. 31%, respectively) (Table 4). The differenti-
tion in survival between these 4 different cohorts became
ore significant at 6 months (Fig. 4) (chi-square  81.2)
han at 3 months, further showing the greater differen-
iation in survival over time (Table 4).
Figure 2 Prevalence of Baseline
Anemia Stratified by Age and Gender
Bar graph illustrating the prevalence of anemia according
to age cohorts and differences in rates between men and women.
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he key finding in our single-center heart failure cohort is
hat anemia in patients with chronic heart failure has been
nderrecognized and underevaluated in clinical practice.
eanwhile, careful follow-up in patients with sequential
valuation of their Hb levels showed that a relatively large
ohort (up to 43% of patients with anemia detected in a
ingle time point at baseline) may proceed with resolution of
heir Hb to their nonanemic levels over time. Particularly
eassuring was the fact that these patients with so-called
ransient anemia may show equivalent long-term outcomes
hen compared with those without any anemia. Our data
lso confirmed prior studies showing that persistent anemia
Figure 3 Anemia Characteristics According to Patient Subgrou
Bar graphs illustrating rates of persistent, transient, incident, or no anemia accord
glomerular filtration rates (eGFR) (median 60 ml/min/1.73 m2); (B) baseline left v
levels (BNP) (median 325 pg/ml); and (D) baseline diabetes status.
ultivariate Nominal Logisticegress on for Independen Prediction of Anemia
Table 2 Multivariate Nominal LogisticRegression for Independent Prediction of Anemia
Baseline Variable Odds Ratio (95% CI) p Value
BNP 325 pg/ml 4.38 (2.67–7.41) 0.0001
eGFR 60 ml/min/1.73 m2 3.04 (1.97–4.72) 0.0001
Diabetes mellitus 2.14 (1.39–3.28) 0.0005
LVEF 30% 0.81 (0.70–0.92) 0.0015
Mean corpuscular volume 90 fl 1.85 (1.22–2.78) 0.004
Male 1.62 (1.02–2.63) 0.047
Age 65 yrs 1.20 (0.78–1.86) 0.41
Hypertension 0.83 (0.55–1.26) 0.39
LA area 25 cm2 1.03 (0.66–1.59) 0.91NP B-type natriuretic peptide; CI confidence interval; eGFR estimated glomerular filtration
ate; LA  left atrial; LVEF  left ventricular ejection fraction. An patients with mild-to-moderate heart failure confers a
igher risk for mortality compared with patients with
esolved, new-onset, or no anemia.
Although many heart failure studies have shown that
nemia (often determined at a single time point) was
ssociated with worse prognosis (3,13–16) , few have ex-
lored the impact of longitudinal changes in anemia status
s well as the consequences of these changes on clinical
utcomes. Our findings complement prior observations
rom post hoc analysis of the Val-HeFT (Valsartan in Heart
subgroups above versus below median values, including (A) baseline estimated
lar ejection fraction (LVEF) (median 30%); (C) baseline B-type natriuretic peptide
ultivariate Risk Ratiosor Independent Prediction of All-Cause Mortality
Table 3 Multivariate Risk Ratiosfor Independent Prediction of All-Cause Mortality
Baseline Variable Increment
Multivariate Risk Ratio
(95% CI) p Value
Hemoglobin (g/dl) 1 0.85 (0.77–0.94) 0.0016
Age (yrs) 10 1.29 (1.11–1.50) 0.0005
Gender (male/female) 1 (male) 1.86 (1.25–2.83) 0.0019
Diabetes (yes/no) 1 (yes) 1.36 (0.95–1.93) 0.090
eGFR (ml/min/1.73 m2) 10 0.92 (0.86–0.98) 0.011
LVEF (%-U) 10 0.93 (0.82–1.05) 0.22
LA area (cm2) 10 1.34 (1.13–1.55) 0.0014
BNP (pg/ml) 100 1.03 (1.01–1.05) 0.0014
Systolic blood pressure
(mm Hg)
10 0.90 (0.83–0.98) 0.011
Heart rate (beats/min) 10 1.07 (0.94–1.20) 0.30
Sodium (mEq/l) 10 0.88 (0.56–1.42) 0.59
Total cholesterol (mg/dl) 10 0.96 (0.92–1.01) 0.095ps
ing to
entricubbreviations as in Table 2.
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Anemia in Ambulatory Heart Failure Patients February 5, 2008:569–76ailure Trial) and COMET (Carvedilol or Metoprolol
valuation Trial), showing patients with the largest de-
rease in Hb levels fared the worse in hospitalization,
orbidity, and mortality (17). The fact that a substantial
roportion of patients had transient anemia (despite the fact
hat only 21% were on iron supplementation and 8% were
n erythropoiesis stimulating agents) may imply the hetero-
eneity of the patient population when anemia was deter-
ined only at a single time point. Furthermore, our data
howed that patients with no or transient anemia have
urvival rates significantly better than those of patients with
ersistent anemia. This finding may imply that a single-
ime-point evaluation of Hb may not reflect the true
rognostic value of low Hb levels because resolution of
nemia may occur especially when the development of
nemia at that time point was influenced by other concom-
tant and potentially reversible conditions. Because only a
inority of patients received treatment for anemia, it is
onceivable that anemia in a substantial number of patients
ay have resolved after standard heart failure management,
Figure 4 Kaplan-Meier Analysis of All-Cause
Mortality According to Anemia Status
Stratified according to (A) presence or absence of anemia at
baseline and to (B) persistent, transient, incident, or no anemia at follow-up.articularly with better control of fluid status (leading to less oilutional anemia) and neurohormonal antagonism. Indeed,
recent publication has also challenged the adverse contri-
ution of a diagnosis of anemia at the time of new-onset
iagnosis of heart failure to long-term clinical outcomes
ecause the prognostic value of anemia became less apparent
hen adjusted for other known prognostic variables (age,
iastolic blood pressure, serum creatinine, New York Heart
ssociation functional class, and left ventricular function)
18). We were unable to identify reliable predictors of
ransient versus persistent anemia, therefore careful moni-
oring and evaluation of sequential Hb levels over time
emains the recommended approach.
In our overall study cohort of 6,159 patients, the 17%
o 23% prevalence of anemia is consistent with that
eported in the literature (4). The majority of patients
ith anemia (70%) showed normocytic indices, which
ay influence the perceived need for a more aggressive
orkup. Up to one-fifth of our anemia patients had
icrocytic anemia, and many patients may have specific
easons for anemia (such as iron deficiency anemia,
halassemia, renal insufficiency, or occult gastrointestinal
leeding) even with normal erythrocyte volumes. The
ost likely explanation is still the fact that Hb levels have
ot been commonly recognized as a relevant measure-
ent in the management of heart failure until recently.
his is particularly apparent in cardiology clinics, where
he primary focus of managing heart conditions has
istracted from evaluating or even establishing a diagno-
is of anemia.
The reported incidence of new-onset anemia (12% to
5% within 6 months) in patients with heart failure
eserved further discussion and investigation. Excessive
CE inhibition may suppress the degradation of inhib-
tors of hematopoiesis, resulting in iatrogenic anemia
19). The majority of our patient population had already
een receiving ACE inhibitors for some duration, there-
ore the impact of an ACE inhibitor-induced reduction
n Hb levels may not be as relevant (17,20). Nevertheless,
hese data were comparable with the 14.1% incidence of
nemia at year 1 from COMET using less stringent
nemia criteria (Hb 13 g/dl for men and 12 g/dl for
omen) (21). Regardless, the number of patients who
ay still have persistent anemia or may have developed
ew-onset anemia within 3 to 6 months of initial
valuation (approximately 30%) implies that sequential
valuation of complete blood count may be clinically
seful. As expected, anemia is also more common in
atients with diabetes mellitus, who may also have more
ardiac and renal compromise. Patients with higher
lasma BNP levels also were expected to have low Hb
evels (22,23). Better understanding of the factors leading
o the development of anemia in heart failure will likely
rovide potential insights into disease mechanisms and
otential therapeutic targets. In particular, whether spe-
ific therapy targeting optimal Hb levels (such as the use
f erythropoiesis-stimulating agents) can benefit long-
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24 –26) remains to be proven in large multicenter ran-
omized controlled trials, particularly with recent studies
n the chronic kidney disease population that have failed
o show significant benefits with the use of erythropoietin
herapy to achieve higher Hb targets (27,28).
The strength of our data from electronic medical
ecords lies in our ability to easily track our patient cohort
ver time in real clinical practices. This study shows the
ower of using electronic medical records as a unique and
ovel way to further our understanding of practice
atterns as well as disease characteristics and outcomes.
etailed information such as anemia subtypes (such as
icrocytic vs. macrocytic), concomitant conditions (such
s renal insufficiency), and diagnostic workup patterns (or
he lack of follow-up evaluation) can be determined
irectly from the clinical laboratory data of the electronic
edical records. The striking contrast between the doc-
mented diagnosis of anemia and the documented Hb
evels can illustrate some advantages of this research
trategy over administrative database interrogation. In
urn, future quality assurance measures can be imple-
ented directly into the electronic medical record system
o improve diagnostic and coding accuracy via reminder
ystems or automatic coding algorithms.
Our study is limited by its retrospective design, and the
andate to have an available complete blood count
ssessment (at baseline and especially at pre-defined
ntervals) may not represent the true prevalence of an
nselected heart failure population. Furthermore, a single
utoff value (even with gender-specific definitions) may
imit the reliability of the estimation of the prevalence
nd incidence rates by values that were borderline, even
hen an 0.5 g/dl increase in Hb levels was instituted to
ncrease the reliability of assessing the changes in the
ollow-up Hb levels. The lack of consistent objective
easurements of fluid overload as well as physician-
ssessed or self-reported functional status (such as New
ork Heart Association functional classification) at spe-
ific time intervals may have limited the accuracy of
etermining concomitant changes in clinical status with
ortality Risk Ratios by Anemia Status at Baseline and Follow-Up
Table 4 Mortality Risk Ratios by Anemia Status at Baseline an
Subgroup 1
Comparison
Subgroup 2
Comparison
Short-Te
Risk Ra
Persistent anemia No anemia at baseline and follow-up 1.68
Persistent anemia No anemia at baseline 1.61
Persistent anemia Resolved anemia 1.73
Persistent anemia Incident anemia 1.30
Incident anemia No anemia at baseline and follow-up 1.29
Incident anemia Resolved anemia 1.35
Resolved anemia No anemia at baseline and follow-up 0.98
Resolved anemia No anemia at baseline 0.93
p  0.0001. †p  0.05. ‡p  0.05. §p  0.001.
CI  confidence interval.hanges in Hb over time. The arbitrary criteria set for the aollow-up durations may have limited the sample size of
he follow-up subgroups, and can introduce selection bias
n favor of those for whom follow-up evaluation were
eemed necessary (which may have explained the higher
revalence of anemia at follow-up). The practice patterns
ay underestimate the true rates of evaluation because
atients may seek care outside our hospital system,
lthough the majority of the patients in this analysis have
eceived long-term follow-up in internal medicine and
ardiology clinics. It is also difficult to adjust for varia-
ions in treatment effects based on sequential Hb levels
ecause the small subgroup of patients undergoing iron or
rythropoietin treatment were initiated on therapy only
fter the follow-up time interval, and a definitive diag-
osis of iron deficiency was not available in a large
umber of individuals with anemia at baseline even with
icrocytic anemia. Anemia with normal versus low iron
ay have different relationships to concurrent hemody-
amic measures. Regression of the mean may have
ontributed to our observations, particularly with the
igher resolution rate in patients with eGFR 60 ml/
in/1.73 m2, as the prevalence and incidence of anemia
ere substantially higher in this subgroup. Further stud-
es are needed to determine how to improve the diagnos-
ic workup of anemia for this patient population and how
o identify those who may benefit from specific therapies
argeting anemia associated with heart failure.
onclusions
n our single-center cohort of ambulatory patients with a
linical diagnosis of heart failure with available complete
lood count assessment, anemia was underrecognized and
nderevaluated, especially in cardiology clinics. Resolution
f anemia was evident in up to 43% of patients who
resented initially with anemia, and did not pose greater
ong-term mortality risks. However, the presence of persis-
ent anemia conferred poorer survival in patients with heart
ailure when compared with that of incident, resolved, or no
low-Up
llow-Up
5% CI) Chi-Square
Long-Term Follow-Up
Risk Ratio (95% CI) Chi-Square
2.06) 23.4* 2.51 (1.99–3.14) 54.4*
1.96) 20.8* 2.19 (1.75–2.71) 41.8*
3.14) 4.4† 2.43 (1.74–3.48) 27.6*
1.75) 3.2‡ 1.33 (1.01–1.76) 4.0†
1.68) 3.5‡ 1.89 (1.48–2.38) 25.0*
2.49) 1.1‡ 1.82 (1.29–2.61) 11.8§
1.61) 0.1‡ 0.98 (0.73–1.36) 0.1‡
1.53) 0.1‡ 0.90 (0.65–1.20) 0.5‡d Fol
rm Fo
tio (9
(1.37–
(1.32–
(1.03–
(0.98–
(0.99–
(0.78–
(0.54–
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